Home
overview

“Effective Life-Cycle Management (LCM) is a critical factor governing successful commercialisation of pharmaceutical R&D output and this meeting will provide an excellent insight into strategies adopted across the industry”

Dr Tim Sparey, Associate Director, Licensing & External Research, Merck Sharp and Dohme

The SMi Group are proud to present their 3rd Annual conference on Pharmaceutical Portfolio & Product Lifecycle Management.
SMi’s 3rd Pharmaceutical Portfolio & Product Lifecycle Management conference will be held on Wednesday 2nd and Thursday 3rd July, 2008, in central London. This conference offers a unique opportunity to hear about the latest developments in Portfolio & Product Life Cycle Management from industry leaders.

The conference will focus on these key areas:
  • Strategic portfolio management and planning
  • Pairing in-house and alliance products
  • Licensing and portfolio management
  • Strong branding in life-cycle management
  • Forecasting analysis and incorporating risk and uncertainty into this
  • Winning deal strategies
  • Emerging markets and therapy areas
  • Pricing analysis
  • Future Mapping Commercial Opportunity
  • Balancing technical and commercial risk in portfolios
  • Authorized generics
  • Reformulation as a LCM strategy
  • Secondary patent strategies
  • Embedding Portfolio and Lifecycle management in the organization as a permanent, continuous process and core structural component.
  • Elaborating the strategy and effectively articulating it’s importance to your organization
  • Defining effective processes and allocating appropriate resources
  • Re-Aligning priorities (e.g. between NPD & LCM)
  • Aligning incentives throughout development - resolving conflicts
  • Filing trends and how innovators and generics are using patents to manage life-cycles.
Our exceptional speaker line-up includes:
  • Dr Tony Ellery, Global Head of Project Management for Mature Products, Novartis
  • Dr Rodger Holdsworth, Head, R & D Portfolio Management, UCB
  • Dr James Eshelby, Director, Worldwide Business Development, Pfizer
  • Dr Harald Nusser, Head of Portfolio Management, Bayer Schering Pharma AG
  • Dr Mellor Henessey, Portfolio Management Director, AstraZeneca
  • Dr Stuart Williams, Vice President, Mylan Labs
  • William Haddad, Chairman & Chief Executive Officer, Biogenerics Inc.
  • Peter Elsig Raun, Senior Analyst, Market Research & Competitive Intelligence - Strategic Marketing, Lundbeck A/S
  • Professor Karrar Kahn, Former Director, Pharmaceutical Development, OSI Pharmaceuticals
  • Dr Duncan Curley, Director, Innovative Legal
  • Dr Alan Norris, Director, Strategic Alliances, Gastrointestinal Disease Area, Novartis
  • Marc Sluijs, EMEA Business Development Director, Oracle
  • Mike Rea, Chief Executive Officer, IdeaPharma
  • Bruce D. Sunstein, Attorneys at Law, Bromberg & Sunstein LLP
  • Gina Ford, Executive Director, Boston Healthcare
  • Joseph Ferrara, Executive Vice President, Boston Healthcare
  • Adam Barak, Director, PharmaPrice International
  • Ralph Villiger, Managing Director, Avance
You will benefit from attending this event if you are:
Vice Presidents, Directors, Managers and Associates from:
<><><><><>
·          Product Lifecycle Management
·          Commercial Development
·          Commercial Strategy
·          Portfolio Management
·          Marketing Analysis
·          Brand Management
·          Product Management
·          Product Development
·          Global Strategy
·          Project Management
·          Marketing
·          Business Analysis
·          Market Research
·          New Product Planning
·          New Product Management
·          Business Intelligence
·          Strategic Planning/Marketing
·          Portfolio Planning
·          Business Development
·          Licensing
·          New Product Planning
·          Strategic Marketing
·          R&D Management
For Speaking opportunities please contact Simon Curtis at scurtis@smi-online.co.uk
For Sponsorship opportunities please contact Alia Malick at amalick@smi-online.co.uk

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

James Eshelby

James Eshelby, Director, Worldwide Business Development, Pfizer

9:10 THE PLANNING CHALLENGES OF GENERIC BIOTECH

William Haddad

William Haddad, Chairman & Chief Executive Officer, Biogenerics

  • Planning for the next generation of generics
  • How to approach the problems and the opportunities of what will become an essential part of manufacturing of products
  • Timing of market entry, regulatory requirements, pricing and in general a new "science"
  • Potential profit margins are greater than traditional generic products (after amortized start-up costs)
  • Entry into an expanding the next generation of pharmaceuticals
  • 9:50 BRINGING GENERICS TO THE US MARKETS

    Stuart Williams

    Stuart Williams, Partner, Wilson Sonsini Goodrich & Rosati

    10:30 Morning Coffee

    11:00 NAVIGATING THE PAYER CONTINUUM

    David Parker

    David Parker, Vice President, Boston Healthcare Associates

  • Practices in evaluating the reimbursement landscape
  • Techniques to gauge price elasticity according to product access requirements
  • Market entry reimbursement messages to foster early adoption
  • Long-term planning to support utilization according to reimbursement requirements
  • 11:40 PANEL DISCUSSION

  • Comparing and Combining: Optimizing LCM strategy mix
  • Understanding regulatory and reimbursement risk
  • Assessing value in the context of shifting stakeholder needs and motivations
  • Implementation of LCM: integrating processes and metrics effectively and broadly
  • Case Studies: opportunities and challenges
  • Tony Ellery

    Tony Ellery, Head of Life Cycle Management, Novartis

    Roger Holdsworth

    Roger Holdsworth, Head - R&D Portfolio Management, UCB Group

    Mellor Henessey

    Mellor Henessey, Global Portfolio Strategist, AstraZeneca

    Adam Barak

    Adam Barak, Director, ABPPC Ltd

    Joseph Ferrara

    Joseph Ferrara, Executive Vice President, Boston Healthcare Associates

    12:20 Networking Lunch

    13:20 ACTIVE PORTFOLIO MANAGEMENT IN PHARMACEUTICAL DEVELOPMENT

    Harald Nusser

    Harald Nusser, Head of Portfolio Management, Bayer Schering Pharma

  • Balancing risk and reward in strategic project prioritization
  • Beyond strategic claim: Day to day reality
  • Bridging strategic claim and operational reality
  • 14:00 ADDING VALUE THROUGH PRODUCT DEVELOPMENT

    Karrar Khan

    Karrar Khan, Former Director, Pharmaceutical Development, OSI Pharmaceuticals

  • Opportunities for drug delivery to extend a product life cycle
  • Developing improved products
  • Designing technical, clinical and commercial benefits into products
  • 14:40 Afternoon Tea

    15:00 BUILDING A STRATEGIC PORTFOLIO PLATFORM

    Marc Sluijs

    Marc Sluijs, EMEA Business Development Director, Oracle

  • Pharma increasingly depends on 3 key capabilities to drive competitive advantage: 1) Portfolio Management, 2) LCM, 3)Alliances & BD&L
  • These – relatively new – capabilities are often still managed in a non-structured, ad-hoc manner
  • This puts companies at risk of losing valuable knowledge, taking sub-optimal decisions with major impact on pipeline and revenue, as well as losing major opportunities to competition. 
  •  Find out how a more strategic approach to managing processes and information can help companies to strengthen the 3 capabilities that will increasingly determine future success
  • 15:40 PARTNERING TO ENHANCE SUCCESSFUL LIFE CYCLE MANAGEMENT

    James Eshelby

    James Eshelby, Director, Worldwide Business Development, Pfizer

  • What is driving this change?
  • What are the opportunities and challenges?
  • How do you maximise your chances for a successful alliance?

  • 16:20 SHAPING BUSINESS DEVELOPMENT THROUGH COLLABORATION VENTURES

    Alan Norris

    Alan Norris, Director, Strategic Alliances, , Novartis

  • What we look to achieve in early stage research collaborations
  • Extending knowledge gathering beyond existing in-house capabilities
  • Gauging the value of a partnership beyond the scope of the deal
  • Outsourcing lead finding and early development to partnering companies with novel technologies
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Roger Holdsworth

    Roger Holdsworth, Head - R&D Portfolio Management, UCB Group

    9:10 SUCCESS FACTORS FOR LCM

    Tony Ellery

    Tony Ellery, Head of Life Cycle Management, Novartis

  • Organizing for success - structure and process
  • What LCM measures have worked well in the past?
  • What will work in the future?
  • 9:50 LEVERAGING BPM TO DRIVE A MORE EFFECTIVE PORTFOLIO DECISION MAKING PROCESS

    Mellor Henessey

    Mellor Henessey, Global Portfolio Strategist, AstraZeneca

  • Harnessing the power of Networks
  • Benefits of aligning Business Performance Management with Portfolio Management
  • Balancing soft (behaviour, skills, capabilities) and hard (data, analytics, models)
  • Case study from AstraZeneca
  • 10:30 Morning Coffee

    11:00 THE IMPORTANCE AND IMPLEMENTATION OF PORTFOLIO MANAGEMENT

    Roger Holdsworth

    Roger Holdsworth, Head - R&D Portfolio Management, UCB Group

  • There is an increasing need for informed decision making in the pharmaceutical industry
  • Many techniques are available for the evaluation of portfolios and the projects they contain
  • It is important to use the appropriate techniques at different stages of development
  • Effective communication to the appropriate people is key
  • 11:40 VALUATION IN PORTFOLIO MANAGEMENT

    Ralph Villiger

    Ralph Villiger, Partner, Avance

  • Different valuation methods: DCF/rNPV, Decision tree, Real Options
  • How to set up a portfolio valuation
  • Capture the portfolio dynamics
  • Risk measures
  • Compare different development plans
  • Optimisation
  • 12:20 Networking Lunch

    13:50 FORECASTING ANALYSIS AND INCORPORATING RISK AND UNCERTAINTY INTO THIS

    Peter Elsig Raun

    Peter Elsig Raun, Senior Analyst, Lundbeck Denmark

    • Different approaches to forecasting
    • Forecasting in the changing dynamics of the pharmaceutical industry

    • Forecasting the unpredictable – mitigating the risk

    14:30 SUPPLEMENTARY PROTECTION CERTIFICATES AND PAEDIATRIC EXTENSIONS

    Duncan Curley

    Duncan Curley, Director, Innovate Legal Services Limited

  • New references to the European Court of Justice
  • Combination products: law and practice
  • Paediatric extensions to SPCs
  • 15:10 Afternoon Tea

    15:40 FUTURE MAPPING COMMERCIAL OPPORTUNITY

    Mike Rea

    Mike Rea, Chief Executive Officer, Ideapharma

  • The role of directed exploration and opportunistic evaluation
  •  'Where the streets are paved with gold...': Predicting areas of opportunity and risk - finding virgin unmet need 'headroom'
  • Embracing levels of complexity - overlaying the known and unknown needs and wants of prescribers, regulators, payors and patients
  • The importance of granularity - 'satellite' and 'street-level' mapping 
  • Generating future scenarios - progressions and disruptive events
  • 16:20 STRATEGIC APPROACHES FOR PROTECTING PHARMACEUTICAL INNOVATIONS IN THE CHANGING US PATENT ENVIRONMENT

    Bruce Sunstein

    Bruce Sunstein, Attorneys at Law, Bromberg & Sunstein LLP

  • How to spot patents that are vulnerable to obviousness attacks
  • How to strengthen patents that are vulnerable to such attacks
  • How to write and prosecute patent applications to reduce risks of obviousness attacks
  • How to consider and deal with combination drugs in the new environment
  • How the KSR decision requires changes in patent portfolio management processes
  • How to hedge against rules on hold that may force more compact procedures
  • How to improve efficiency in obtaining US patents
  • 17:00 Chairman’s Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.